Brief: Ipsen To Acquire Imcheck Therapeutics
22/10/2025 06:07
Oct 22 (Reuters) - Ipsen SA IPN.PA: IPSEN TO ACQUIRE IMCHECK THERAPEUTICS, EXPANDING ITS LEADERSHIP IN ONCOLOGY, STRENGTHENING ITS PIPELINE TO BUY IMCHECK THERAPEUTICS FOR 350 MILLION EUROS TOTAL POTENTIAL CONSIDERATION UP TO 1 BILLION EUROS TRANSACTION IS EXPECTED TO CLOSE BY END OF Q1 2026 Source text: ID:nGNX5GqW3V Further company coverage: IPN.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients